Fresenius Medical Care - FMS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $24.00
  • Forecasted Upside: 12.52%
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.08 (0.38%)

This chart shows the closing price for FMS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fresenius Medical Care Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FMS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FMS

Analyst Price Target is $24.00
▲ +12.52% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Fresenius Medical Care in the last 3 months. The average price target is $24.00, with a high forecast of $24.00 and a low forecast of $24.00. The average price target represents a 12.52% upside from the last price of $21.33.

This chart shows the closing price for FMS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 7 investment analysts is to hold stock in Fresenius Medical Care. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2024Truist FinancialBoost TargetHold ➝ Hold$21.00 ➝ $24.00Low
1/8/2024Morgan StanleyDowngradeEqual Weight ➝ UnderweightLow
11/24/2023HSBCUpgradeReduce ➝ HoldLow
11/17/2023Societe GeneraleUpgradeHold ➝ BuyLow
10/11/2023Truist FinancialLower TargetHold ➝ Hold$28.00 ➝ $24.00Low
9/13/2023UBS GroupUpgradeSell ➝ NeutralLow
8/16/2023Morgan StanleyBoost Target€40.50Low
8/14/2023UBS GroupDowngradeBuy ➝ NeutralLow
8/1/2023CitigroupInitiated CoverageNeutralLow
7/13/2023Truist FinancialBoost TargetHold$26.00 ➝ $28.00Low
7/12/2023The Goldman Sachs GroupInitiated CoverageBuyLow
4/28/2023Deutsche Bank AktiengesellschaftUpgradeSell ➝ HoldLow
4/13/2023Truist FinancialBoost TargetHold$22.00 ➝ $24.00Low
3/7/2023HSBCDowngradeHold ➝ ReduceLow
3/7/2023Sanford C. BernsteinInitiated CoverageMarket PerformLow
2/23/2023Truist FinancialBoost TargetHold$17.00 ➝ $22.00Low
1/2/2023Jefferies Financial GroupDowngradeBuy ➝ Underperform$14.00 ➝ $11.70Low
11/9/2022Credit Suisse GroupLower Target€37.00 ➝ €32.00Low
11/3/2022Deutsche Bank AktiengesellschaftLower TargetSell ➝ Sell€24.00 ➝ €22.00Low
11/2/2022Morgan StanleyLower TargetEqual Weight ➝ Equal Weight€34.00 ➝ €33.00Low
11/1/2022JPMorgan Chase & Co.Lower Target€23.00 ➝ €17.10Low
10/28/2022BarclaysLower TargetEqual Weight ➝ Equal Weight€40.00 ➝ €36.00Low
10/26/2022Berenberg BankLower Target€57.95 ➝ €51.80Low
10/26/2022Deutsche Bank AktiengesellschaftDowngradeHold ➝ Sell€37.00 ➝ €24.00Low
10/18/2022Morgan StanleyInitiated CoverageEqual WeightLow
10/10/2022Jefferies Financial GroupDowngradeBuy ➝ HoldLow
8/10/2022Berenberg BankLower Target€76.70 ➝ €57.95Low
8/1/2022JPMorgan Chase & Co.Lower Target€51.00 ➝ €23.00Low
7/29/2022DZ BankDowngradeBuy ➝ HoldLow
7/29/2022UBS GroupDowngradeBuy ➝ NeutralLow
6/27/2022Jefferies Financial GroupUpgradeUnderperform ➝ Buy$30.30 ➝ $33.70Low
6/22/2022Truist FinancialLower TargetHold$34.00 ➝ $27.00Low
5/5/2022JPMorgan Chase & Co.Boost TargetUnderweight ➝ Underweight€48.70 ➝ €51.00Low
3/17/2022Berenberg BankLower Target€84.90 ➝ €83.40Low
3/1/2022Oddo BhfUpgradeNeutral ➝ Outperform€72.00Low
3/1/2022Credit Suisse GroupLower Target€66.00 ➝ €61.00Low
2/25/2022Societe GeneraleLower Target€61.00 ➝ €57.00Low
2/11/2022Jefferies Financial GroupDowngradeHold ➝ Underperform$32.40 ➝ $30.30Medium
12/1/2021Deutsche Bank AktiengesellschaftReiterated RatingHoldMedium
11/23/2021HSBCInitiated CoverageHoldMedium
11/17/2021Royal Bank of CanadaLower TargetSector Perform$42.00 ➝ $35.00Medium
11/11/2021Jefferies Financial GroupUpgradeUnderperform ➝ HoldLow
11/10/2021Berenberg BankReiterated RatingBuyLow
11/9/2021JPMorgan Chase & Co.Reiterated RatingUnderweightLow
11/5/2021Deutsche Bank AktiengesellschaftReiterated RatingHoldLow
10/26/2021Deutsche Bank AktiengesellschaftReiterated RatingHoldLow
10/21/2021BarclaysReiterated RatingEqual WeightLow
10/13/2021Truist FinancialLower TargetHold$44.00 ➝ $40.00Low
9/10/2021BarclaysDowngradeOverweight ➝ Equal WeightMedium
9/10/2021JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMedium
8/11/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
8/4/2021Societe GeneraleReiterated RatingHoldLow
7/21/2021Deutsche Bank AktiengesellschaftReiterated RatingHoldMedium
7/20/2021UBS GroupReiterated RatingBuyLow
5/12/2021Nord/LBUpgradeHold ➝ BuyMedium
5/11/2021DZ BankReiterated RatingBuyLow
5/10/2021Credit Suisse GroupReiterated RatingNeutralLow
4/28/2021BarclaysReiterated RatingOverweightLow
3/2/2021Berenberg BankReiterated RatingBuyMedium
2/26/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
2/24/2021Truist FinancialDowngradeBuy ➝ HoldLow
2/17/2021UBS GroupReiterated RatingBuyMedium
2/5/2021Berenberg BankReiterated RatingBuyLow
2/4/2021BNP ParibasDowngradeOutperform ➝ NeutralLow
2/4/2021Exane BNP ParibasDowngradeOutperform ➝ NeutralMedium
2/4/2021Kepler Capital MarketsDowngradeBuy ➝ HoldLow
2/4/2021JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
2/3/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldLow
2/3/2021DZ BankReiterated RatingBuyLow
2/3/2021The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyHigh
2/2/2021BarclaysReiterated RatingOverweightLow
2/1/2021Stifel NicolausDowngradeBuy ➝ HoldLow
1/11/2021Jefferies Financial GroupDowngradeHold ➝ UnderperformMedium
1/6/2021Nord/LBReiterated RatingBuyN/A
12/9/2020Morgan StanleyReiterated RatingEqual WeightLow
11/19/2020Royal Bank of CanadaReiterated RatingNeutralLow
11/10/2020Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
11/5/2020UBS GroupReiterated RatingBuyLow
11/4/2020Nord/LBUpgradeHold ➝ BuyLow
10/30/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
10/30/2020Morgan StanleyReiterated RatingEqual WeightLow
10/13/2020Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
9/3/2020JPMorgan Chase & Co.Reiterated RatingBuyHigh
8/18/2020Morgan StanleyReiterated RatingEqual WeightLow
8/13/2020Royal Bank of CanadaReiterated RatingNeutralLow
8/5/2020Jefferies Financial GroupDowngradeBuy ➝ HoldLow
8/3/2020DZ BankReiterated RatingBuyLow
7/28/2020Berenberg BankReiterated RatingBuyLow
7/17/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
6/1/2020BarclaysReiterated RatingOverweightLow
5/21/2020SunTrust BanksBoost TargetBuy$46.00 ➝ $48.00Low
5/20/2020Morgan StanleyUpgradeUnderweight ➝ Equal WeightLow
5/19/2020JPMorgan Chase & Co.Reiterated RatingOverweightHigh
5/14/2020Kepler Capital MarketsUpgradeHold ➝ BuyLow
5/11/2020SunTrust BanksBoost TargetBuy$42.00 ➝ $46.00Low
5/7/2020DZ BankReiterated RatingBuyLow
4/27/2020BarclaysReiterated RatingOverweightMedium
4/20/2020Royal Bank of CanadaReiterated RatingHold$42.00Low
4/17/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyLow
4/13/2020SunTrust BanksLower TargetBuy$46.00 ➝ $42.00Medium
3/23/2020UBS GroupReiterated RatingBuyMedium
3/19/2020DZ BankReiterated RatingBuyMedium
3/3/2020BarclaysReiterated RatingBuyLow
2/25/2020DZ BankReiterated RatingBuyMedium
2/21/2020CfraUpgradeHold ➝ Buy$38.00 ➝ $46.00Low
1/21/2020Jefferies Financial GroupUpgradeHold ➝ Buy$44.50Low
12/6/2019Morgan StanleyDowngradeEqual Weight ➝ UnderweightLow
10/30/2019DZ BankReiterated RatingNeutralLow
10/23/2019Redburn PartnersReiterated RatingBuy ➝ NeutralLow
8/29/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
8/19/2019Royal Bank of CanadaReiterated RatingNeutralLow
8/1/2019BTIG ResearchDowngradeBuy ➝ NeutralLow
7/30/2019DZ BankReiterated RatingNeutralLow
7/11/2019DZ BankReiterated RatingNeutralLow
6/20/2019BarclaysUpgradeEqual Weight ➝ Overweight$40.23Low
6/6/2019Royal Bank of CanadaReiterated RatingNeutralLow
(Data available from 5/28/2019 forward)

News Sentiment Rating

0.90 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 12 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
  • 6 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 5 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 10 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 8 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 9 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 12 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Current Sentiment

  • 12 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Fresenius Medical Care logo
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Read More

Today's Range

Now: $21.33
Low: $21.08
High: $21.41

50 Day Range

MA: $20.19
Low: $18.39
High: $22.41

52 Week Range

Now: $21.33
Low: $16.37
High: $27.72


405,594 shs

Average Volume

438,943 shs

Market Capitalization

$12.52 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Fresenius Medical Care?

The following Wall Street analysts have issued research reports on Fresenius Medical Care in the last twelve months: Citigroup Inc., HSBC Holdings plc, Morgan Stanley, Societe Generale,, The Goldman Sachs Group, Inc., Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for FMS.

What is the current price target for Fresenius Medical Care?

1 Wall Street analysts have set twelve-month price targets for Fresenius Medical Care in the last year. Their average twelve-month price target is $24.00, suggesting a possible upside of 13.4%. Truist Financial Co. has the highest price target set, predicting FMS will reach $24.00 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $24.00 for Fresenius Medical Care in the next year.
View the latest price targets for FMS.

What is the current consensus analyst rating for Fresenius Medical Care?

Fresenius Medical Care currently has 1 sell rating, 4 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in FMS, but not buy more shares or sell existing shares.
View the latest ratings for FMS.

What other companies compete with Fresenius Medical Care?

Other companies that are similar to Fresenius Medical Care include DaVita, Sotera Health, Progyny, agilon health and Viemed Healthcare. Learn More about companies similar to Fresenius Medical Care.

How do I contact Fresenius Medical Care's investor relations team?

Fresenius Medical Care's physical mailing address is ELSE-KROENER STRASSE 1, BAD HOMBURG 2M, 61352. The company's listed phone number is (496) 172-6090 and its investor relations email address is [email protected]. The official website for Fresenius Medical Care is Learn More about contacing Fresenius Medical Care investor relations.